Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Alkermes Inc patents


Recent patent applications related to Alkermes Inc. Alkermes Inc is listed as an Agent/Assignee. Note: Alkermes Inc may have other listings under different names/spellings. We're not affiliated with Alkermes Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Alkermes Inc-related inventors


Reduction of flake-like aggregation in nanoparticulate active agent compositions

This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. ... Alkermes Inc

Multi-api loading prodrugs

The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. Prodrug conjugates are suitable for sustained delivery of heteroaryl, lactam- amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, acylaniline-, cyclic amide- and tertiary amine-containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties. ... Alkermes Inc

Heterocyclic compounds for the treatment of neurological and psychological disorders

Lactam compounds of formula i and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.. . ... Alkermes Inc

Sustained release aminopyridine composition

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulations, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.. . ... Alkermes Inc

Alcohol resistant enteric pharmaceutical compositions

Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof.. . ... Alkermes Inc

Naltrexone long acting formulations and methods of use

. . The inventions described herein arose from unexpected discoveries made during clinical trials with a long acting formulation of naltrexone. As such, the invention includes a method for treating an individual in need of naltrexone comprising the step of parenterally administering a long acting formulation comprising naltrexone and to the use of naltrexone in the manufacture of medicaments for use in such methods.. ... Alkermes Inc

Prodrugs of fumarates and their use in treating various diseases

The present invention provides compounds of formula (i), and pharmaceutical compositions thereof.. . ... Alkermes Inc

Sustained release aminopyridine composition

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.. . ... Alkermes Inc

Prodrugs of fumarates and their use in treating various diseases

The present invention provides compounds of formula (i), and pharmaceutical compositions thereof.. . ... Alkermes Inc

Morphan and morphinan analogues, and methods of use

. . The present application relates to analogues of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof.. . ... Alkermes Inc

Pharmaceutical compositions having improved storage stability

The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent. . ... Alkermes Inc

Morphinan derivatives for the treatment of drug overdose

. . The instant application relates to morphinan derivatives of formula i with sustained effectiveness in treating drug toxicity and overdose:. . ... Alkermes Inc

Process for synthesizing oxidized lactam compounds

The invention provides a method for the synthesis of dehydrogenated lactam drugs of formula i:. . ... Alkermes Inc

Sustained release aminopyridine composition

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.. . ... Alkermes Inc

08/17/17 / #20170231981

Compositions of multiple aripiprazole prodrugs

Described herein is a composition comprising: (a) a first population of particles of a first aripiprazole prodrug; and (b) a second population of particles of a second aripiprazole prodrug, different to the first aripiprazole prodrug. At least one of the first and second prodrug populations has a volume based particle size (dv50) of less than about 1000 nm. ... Alkermes Inc

08/03/17 / #20170216279

Methods for treating depressive symptoms

The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of formulas i, ii, iii, and iv, as well as the compounds of table a.. ... Alkermes Inc

07/27/17 / #20170209430

Polymorphic forms of naltrexone

This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.. ... Alkermes Inc

07/13/17 / #20170196856

Pharmaceutical compositions comprising sorbitan esters

The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.. . ... Alkermes Inc

07/13/17 / #20170196848

Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives

The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. ... Alkermes Inc

06/15/17 / #20170165245

Sustained release aminopyridine composition

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.. . ... Alkermes Inc

06/08/17 / #20170157117

Aripiprazole formulations having increased injection speeds

The present invention relates to pharmaceutical compositions comprising a compound of formula (i) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.. . ... Alkermes Inc

05/18/17 / #20170136004

Opioid agonist antagonist combinations

The invention relates a composition comprising an opioid agonist and compound-1:. . ... Alkermes Inc

05/11/17 / #20170129851

Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases

The present invention provides compounds and pharmaceutical compositions for treating neurological diseases such as multiple sclerosis.. . ... Alkermes Inc

05/04/17 / #20170119757

Methods for treating antipsychotic-induced weight gain

The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.. ... Alkermes Inc

04/27/17 / #20170112827

Morphinan derivatives with high oral bioavailability

The instant application relates to morphinan derivatives of formula i with enhanced oral bioavailability for the treatment of diseases associated with opioid receptor activity or blockade including alcohol and opiate addiction.. . ... Alkermes Inc

04/06/17 / #20170095439

Prodrugs of fumarates and their use in treating various diseases

The present invention provides compounds of formula (i), and pharmaceutical compositions thereof.. . ... Alkermes Inc

03/02/17 / #20170056505

Polymer-based sustained release device

. . This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.. ... Alkermes Inc

02/16/17 / #20170044228

Ligands modified by circular permutation as agonists and antagonists

. . The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof.. ... Alkermes Inc

02/02/17 / #20170027874

Sustained release aminopyridine composition

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.. . ... Alkermes Inc

01/19/17 / #20170015659

Prodrugs of nh-acidic compounds

The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. ... Alkermes Inc

01/12/17 / #20170007609

Peripherally acting opioid compounds

The invention relates to a compound of formula i, ii, iii, iv or a pharmaceutically acceptable ester or prodrug thereof:. . ... Alkermes Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Alkermes Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Alkermes Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###